As a supplier of Rapid COVID-19 Antigen Self Test with the largest production and sales in the world, the company has a daily output of 18 million copies, and its sales network has penetrated into more than 120 countries and regions, and has obtained
We can provide Covid-19 Rapid Antigen Test. Test with reliable results within minutes. Made in the USA. Lateral flow assay, No equipment required, Results within 10 minutes, minimally invasive specimen collection, nasal swab, POC (in patient care setting). Detects SARS-CoV2 nucleocapsid protein antigen with ultra high performance. Identifies acute infection with 88.4% sensitivity and 100% specificity. Complies with FDA. Principals or Buyer's Mandates only. No broker chains. FOB or CIF. Minimum order 500000 test please.
Made in Canada
Health Canada approved
CE Mark and ISO certified
The product has proven to have 100% Specificity and 96% Sensitivety
Stock availabity: 2 Million tests/kit in Canada
Production: up to 5 Million tests/kit weekly
The Rapid Response COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset. This test is authorized for use at the Point of Care i.e., in patient care setting. Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigen is generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patientâ??s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The Rapid Responseâ?¢ COVID-19 Antigen Rapid Test Device is for use at the Point of Care for professional use only.
PRODUCT INFORMATION:
Product: Rapid Respose
Sample: Nasal / Nasopharyngeal secretions
Format: Cassette
Quantity: 25 Tests/Kit per box
Time to result: 15 minutes
Storage Condition: 2-30 C/36-86 F
Test Principle: Immunochromatographic Assay
CONTENTS - Individually packed test devices
Extraction Buffer
Extraction tube
Nozzle with filter
Tube stand
Individually packed swabs
Package Insert
380 000 pcs single package SELF-TEST 1pcs KIT Goldsite CE1434
LAIENTEST NASAL
Price start from 1.79
IFU inside EN / DE / PL
BOX PL / EN / DE
Optional PDF IFU FR / IT / ES / DA
Indiaâ??s first COVID-19 test kit for self-use. Get your test results within 15 min from the comfort of your home & Office.
So, there might be a time when you think you have contracted COVID-19 but cannot book a slot for an RT-PCR test. You might be asked to wait a couple of days. In such a circumstance, you can avail of a home/office corona testingÃ? kitÃ? such as Mylab CoviSelf COVID-19 RapidÃ? Antigen Test for COVID.Ã?Â
It is Indiaâ??s first COVID-19 home test kit to have earned the approval of the ICMR. Anyone above the age of 18 can use it at home. However, adult supervision is suggested if the test kit is used by people below 18.
Intelligently Designed
Filled with a solution that inactivates the virus and is designed in a manner to control & contain biohazard.
The Pathocatch Coviself Covid - 19 Rapid Antigen test (RAT) is an in vitro diagnostic test for the qualitative detection of covid - 19 antigen in nasal swab specimens directly from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19.
